Manufacturer
Boehringer Ingelheim Ellas A.E
Contents
Telmisartan
Indication
Essential HTN. Reduction of the risk of MI, stroke or death in patients ≥55 yr at high risk developing major CV events who are unable to take ACE inhibitors. High risk CV events including evidence of CAD, peripheral arterial disease, stroke, transient ischemic attack or DM w/ evidence of end-organ damage. Additional treatment to antihypertensive, antiplatelet or lipid-lowering therapy.
Instruction
May be taken with or without food.
Drug interaction
K-sparing diuretics, K supplements, salt substitutes containing K or other medicinal products that may cause hyperkalaemia (especially digoxin, lithium). Increased hypotensive effect of other antihypertensive agents. Combined treatment w/ NSAIDs should be adequately hydrated & monitored renal function. Combined treatment w/ ACE inhibitors or direct renin-inhibitor aliskiren (not recommended). Monitor serum levels in combined treatment w/ lithium.
Malaysia
